Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Natural History of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

NCT05889988 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05889988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05889988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Natural History of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Active, not recruiting
Start date
June 12, 2023
Completion date
August 31, 2027
Enrollment
36 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm